What is being sold
A commercial station sells access to a pressurised, crewed laboratory and living space in orbit. Its products are crew time (an astronaut's hours spent on a customer's work), crew-days (a visitor living on board), payload accommodation (rack space, power, data and cooling for experiments and production equipment), external mounting points, logistics (upmass and return), and integration and operations services. A station operator also sells the ability to fly: for most customers the station price is bundled with a transport price set by SpaceX or another provider. Understanding demand requires separating the two, because most of a mission's price today pays for the ride.
Market size
Published estimates of the commercial space station market differ by scope and method. The Business Research Company's Q1 2026 estimate puts the market at $5.95 billion in 2025 and $12.93 billion in 2030, a compound growth rate of about 16.8% a year, after historical growth of about 17.1%. Its definition includes ISS-related commercial services, private astronaut missions and station hardware. Other estimates are narrower or wider depending on whether they include transport, payload hardware and government services; some include the whole value of NASA's ISS programme.
Setcoin uses the published figure as an indicator of direction rather than a measure of revenue available to station operators. Most of the value in such estimates is government spending, much of it transport and hardware, and it reaches a station operator only in part. The operator-relevant market in the early 2030s is NASA's services contract plus a few hundred million dollars a year of non-NASA demand.
Six demand segments
| Segment | What is bought | Evidence today | Setcoin view |
|---|---|---|---|
| Government anchor (NASA) | Crew time, research capacity, transport integration | Final RFP issued 9 Oct 2026; two four-person, 30-day increments a year at the revised requirement | Largest and most certain; sets the floor |
| Sovereign astronaut programmes | Missions for countries without a station | Axiom missions have flown astronauts from Saudi Arabia, Turkey, Sweden, Italy, India, Poland and Hungary; more than 10 agencies seek post-ISS access | Most promising non-NASA segment |
| Private astronaut missions | Missions of about two weeks for individuals and organisations | Ax-1 to Ax-4 flown 2022–2025; Ax-5 ordered for no earlier than January 2027; Vast selected for a later mission | Real, but small and lumpy |
| Microgravity research | Rack time and crew time for pharmaceuticals, biology, materials | Long ISS record; pharmaceutical R&D in orbit estimated above $1.8 billion a year in the outline | Growing; mostly government-funded today |
| In-space manufacturing | Production of fibre, crystals, biomaterials | Free-flying capsules (Varda: six missions, $598 million raised) compete for the same work | Unproven at volume; may not need crews |
| Media and brand | Filming, content, sponsorship | ISS productions and private missions; outline estimates a €500 million+ early market | Small, opportunistic |
Government demand
NASA's demand is the anchor of every business plan. Under the August 2025 directive, which the final RFP carries in spirit, NASA's minimum requirement is four crew for one-month increments rather than continuous presence. Two increments a year is 240 crew-days, about a sixth of a four-person station's annual capacity. If NASA reverted to continuous presence of two or more astronauts, as it has on the ISS, its demand alone would fill half or more of a station. That single policy choice is the largest variable in station economics, and it is a policy choice rather than a market one.
International agencies add to government demand. ESA, JAXA and the Canadian Space Agency lose ISS access too, and each is hedging: ESA through memoranda with both Axiom and Starlab and its own cargo programme, JAXA through Mitsubishi's role in Starlab, Canada through MDA Space's robotics contribution. Agencies that today pay for ISS access in barter (hardware, services, crew time) will have to pay cash on a commercial station, which makes them customers rather than partners.
Sovereign astronaut programmes
The most promising non-NASA segment is countries that want their own astronauts in orbit without building a station. Axiom's four missions to the ISS flew private and national astronauts from the United States, Canada, Israel, Saudi Arabia, Turkey, Sweden, Italy, India, Poland and Hungary; for India, Poland and Hungary it was the first national flight in more than four decades. These customers buy a package: astronaut training, the flight, a research programme and the national attention that comes with it. Their budgets are set by governments and their decisions are partly diplomatic, which makes the segment both durable and contested: China is offering Tiangong access to the same countries, starting with Pakistan in 2026.
Private astronaut missions
Private astronaut missions to the ISS have flown at about one a year since 2022. Seats have been reported at about $55 million each, with estimates up to $70 million, and NASA adds its own charges for ISS services: about $5.2 million per person for crew time and $4.8 million per mission for integration and basic services, plus per-day charges for food and supplies. Most of a seat price pays for the Dragon flight. Demand is real but small and price-sensitive; it depends on wealthy individuals and corporate sponsors and responds to the economy and to safety events.
Microgravity research
Research has been the ISS's core product. Pharmaceutical companies have used microgravity to grow protein crystals for structure determination; materials scientists to study combustion, fluids and alloys; biologists to study ageing, muscle and bone loss and tissue growth. The study outline estimates pharmaceutical R&D spending in orbit above $1.8 billion a year, much of it in-kind or government-funded. The commercial question is whether companies will pay full price for research time once the ISS's subsidised access ends. Early evidence is mixed: demand exists, but much of it has relied on grants from the ISS National Laboratory and NASA.
In-space manufacturing
The outline sizes in-space manufacturing at a $2.4 billion addressable market, with candidate products at technology readiness levels 6–7: ZBLAN optical fibre, semiconductor crystals, pharmaceutical formulations and advanced materials. A crewed station is one way to manufacture in orbit, but not the only one. Varda Space Industries crystallises drug compounds in small uncrewed capsules that return to Earth; its first mission spent 47 days in orbit in 2024 growing ritonavir crystals, and it has since completed six launch and re-entry missions and scheduled more than a dozen through 2028. If production can be automated in free-flyers, stations compete for the research and process development, not for the production runs.
The demand paradox
Commercial demand cannot be proven until stations exist, and stations cannot be financed without proven demand. NASA's answer is to be the anchor customer, but anchor tenancy covers only part of the bill: the study outline estimated NASA anchor payments at $40–50 million a year per station, or 20–30% of operating cost. The remaining 70–80% must come from customers whose willingness to pay is untested at scale. One senior commercial station executive was quoted as saying he did not "fundamentally believe there is a market yet" beyond government. The ISS's own history is instructive: it took more than a decade after assembly for the National Laboratory to build a commercial user base, and that base still depends on subsidised access.
Pricing
Station operators sell crew-days, rack-days and integration services. The ISS gives a reference point: NASA's private astronaut mission charges of about $5.2 million per person for crew time and $4.8 million per mission for integration, on top of transport. A commercial station has to price below this total to grow the market, while covering an operating cost estimated at $135–250 million a year per station. At 30% utilisation, capital cost alone runs to about $457,000 per crew-day used (chapter 11). The arithmetic means early stations will price research time well above what most universities and small companies can pay, unless government programmes buy capacity on their behalf.
Utilisation is the binding variable
At a crew of four and a full year of operations a station offers about 1,460 crew-days. NASA's revised requirement buys four-person, 30-day increments: two increments a year is 240 crew-days. Two private astronaut missions of four people for 14 days add 112, and two sovereign missions of two national astronauts for 14 days add 56. That fills about 28% of the crew-days available, with NASA providing about 59% of the time used. Reaching 60% utilisation at the same mission length needs nine more private missions a year. The demand model in this chapter lets the reader change each segment; reaching the utilisation of a mature laboratory requires either continuous NASA presence or a step change in mission cadence.
Geographic demand
Demand is concentrated where human spaceflight programmes and budgets are. North America provides NASA and most private astronauts. Europe provides ESA and national agencies, increasingly interested in commercial access as a substitute for ISS barter. The Middle East and Asia-Pacific provide sovereign astronaut programmes and research investment: Saudi Arabia has flown astronauts commercially, India is building its own station while flying an astronaut on Axiom, and Japan's role in Starlab reflects its interest in post-ISS access. Export controls and political alignment shape who can fly where (chapter 7).